Phase III success for first new gonorrhea treatment in decades

A new first-in-class antibiotic, zoliflodacin, has been shown to be effective in the treatment of gonorrhea, in a Phase III trial.

Sponsored by the Global Antibiotic Research & Development Partnership (GARDP) and a division of Innoviva (Nasdaq: INVA), the trial met its primary endpoint, showing non-inferiority compared with a current global standard of care regimen.

Innoviva Specialty Therapeutics and GARDP hope to address a World Health Organization priority pathogen and bring to market the first new antibiotic for gonorrhea in decades.